Philip Morris Prioritizing Zyn Ultra Marketing -- Market Talk
Dow Jones04-22
1116 ET - Philip Morris International is investing in its Zyn brand with hopes it will drive more growth in the U.S. Investments include marketing, distribution and commercial activations, as well as regular promotional activities, executives say during an analyst call. As part of its efforts, Philip Morris is trying to get Zyn Ultra authorized by the Food and Drug Administration. The application is under active scientific review, which is taking longer than the company expected. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 22, 2026 11:16 ET (15:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments